

February 23, 2026

Dr. Agarwals Health Care Limited: Ratings reaffirmed; rated amount enhanced

Summary of rating action

Instrument*	Previous rated amount (Rs. crore)	Current rated amount (Rs. crore)	Rating action
Long-term – Fund-based – Term loans	88.32	73.80	[ICRA]AA- (Stable); Reaffirmed
Long-term/ Short-term – Unallocated	11.68	126.20	[ICRA]AA- (Stable)/ [ICRA]A1+; Reaffirmed and assigned for enhanced amount
Total	100.00	200.00	

*Instrument details are provided in Annexure I

Rationale

ICRA has taken a consolidated view of Dr. Agarwals Health Care Limited (DAHCL) and its subsidiary Dr. Agarwals Eye Hospital Limited (DAEHL), while assigning the ratings, given the common management and significant financial and operational linkages among the entities. It has also proposed a merger with DAEHL, which is pending shareholder approval.

The rating action reflects the company's established position in India's organised ophthalmology segment, supported by its strong brand equity, proven track record and the promoters' long-standing experience in the eye care industry. DAHCL provides a comprehensive range of eye care services such as cataract, refractive, retinal, corneal, glaucoma and other advanced procedures. It operates on a hub-and-spoke model, anchored by tertiary centres (including centres of excellence (COEs) in Chennai, Tirunelveli and Cuttack) and secondary centres further complemented by primary centres. While primary centres act as patient feeder centres, secondary and tertiary centres offer surgical treatments including specialty and complex surgeries. This day-care, asset-light format enables high patient throughput and faster breakeven timelines, while clustering ensures patient retention within DAHCL's ecosystem.

The ratings also factor in DAHCL's large network of centres and international presence, complemented by a healthy long-term outlook for the health care industry. As of December 31, 2025, DAHCL operated 253 facilities across India and 19 international centres across 9 countries in Africa. The company served 2.2 million patients and performed 2.38 lakh surgeries in 9M FY2026, supported by a team of 908 doctors. ICRA notes that surgeries remain the dominant revenue contributor, accounting for 67% of the company's revenue in 9M FY2026 (65% in FY2025). Within surgeries, cataract operations continue to be the largest segment, with increasing adoption of premium lenses and advanced techniques supporting improvement in yield per patient, in turn supporting the revenues and margins. Aided by increasing footfalls, improving surgical conversions, commencement of new centres and incremental revenues from acquisitions, DAHCL's revenue grew to Rs. 1,711 crore in FY2025 from Rs. 471 crore in FY2021, reflecting a robust compound annual growth rate (CAGR) of 38%. Further, the company's revenue increased by 21.2% year over year to Rs. 1,516 crore in 9M FY2026, facilitated by strong patient footfalls, growth in revenue per surgery and increasing adoption of premium lenses. Supported by healthy revenue growth, the company's operating profit margin (OPM) has also remained healthy and range-bound between 26.7-27.6% over the same duration.

The ratings also consider DAHCL's strong financial profile, aided by the Rs. 300 crore equity infusion through its initial public offering (IPO) in February 2025, which strengthened its liquidity position (cash and liquid investments of Rs. 396.7 crore as on September 30, 2025) and net worth. ICRA notes that of the IPO proceeds, Rs. 195 crore was utilised for debt repayment, leading to improved gearing. While total debt (including lease liabilities) increased marginally to Rs. 982.7 crore as on September 30, 2025 from Rs. 960.9 crore as on March 31, 2025, the total debt (excluding lease liabilities) reduced significantly

to Rs. 179.8 crore from Rs. 246.9 crore over the same period. Additionally, supported by improved operating profits, the leverage metrics also improved with total debt (including lease liabilities)/OPBDITA at 1.9x as on September 30, 2025 and 2.1x as on March 31, 2025 (over 2.6x as on March 31, 2024 and 3.1x as on March 31, 2023). DAHCL's coverage indicators also remain healthy with interest coverage at 5.6x in H1 FY2026, 4.1x in FY2025 over 3.7x in FY2024. As DAHCL operates through an asset-light model wherein it leases space for setting up its eye care centres, ICRA expects the lease liabilities to increase in line with new greenfield centres, while acquisitions (if any) may result in higher net debt levels. ICRA also notes that the company's payor mix is dominated by cash and insurance patients (greater than 90% as on December 31, 2025) which supports healthy margins and keeps working capital intensity low.

However, the ratings remain constrained by DAHCL's sizeable expansion plans of opening 55+ new centres annually, along with reconstruction of its flagship Chennai centre. This is expected to result in Rs. 380-400 crore of capital expenditure (capex) in FY2026. While the capex for opening new centres is anticipated to be funded through DAHCL's internal accruals and existing liquidity, timely execution of the same and subsequent healthy ramp-up of operations at the new centres and the impact of the same on the company's margin trajectory remain monitorable. DAHCL has a put option liability of around Rs. 330 crore for acquiring the remaining 49% stake in Dr. Thind Eye Care Pvt Ltd (DTEPL). While the put option liability for DTEPL is likely to become payable after FY2029, it represents significant future outflows, and the timing and impact of the same on the company's debt metrics and liquidity position will continue to be a key monitorable.

Further, ICRA notes that currently, the revenue profile of DAHCL is skewed as around 63% (as on December 31, 2025) of its revenues come from centres in southern India. DAHCL is mitigating this concentration risk through active diversification via greenfield projects in Maharashtra, Gujarat and Delhi National Capital Region (NCR) in addition to acquisitions of other eye care chains. DAHCL also faces stiff competition from organised chains, unorganised clinics and multi-specialty hospitals, which exert pricing pressure on cataract surgeries and intensify talent acquisition challenges. ICRA notes that the company's doctor-dependent model also entails high consultancy and employee costs, and its ability to retain doctors and experts remains critical for sustaining its surgery mix and patient footfalls. Further, in line with other industry players, DAHCL's performance continues to be exposed to the risk of adverse regulatory measures.

The Stable outlook reflects ICRA's expectation that DAHCL will maintain credit metrics commensurate with the current rating despite significant expansion plans. Further, the outlook underlines ICRA's expectations of timely ramp up of new centres and that the company will be able to manage its acquisition-related liabilities without material weakening of DAHCL's financial profile.

Key rating drivers and their description

Credit strengths

Established brand position in the eyecare segment with experienced promoters - DAHCL has an established presence in India's organised ophthalmology segment, supported by the promoters' long-standing experience in the eye care segment. DAHCL's ability to attract and retain highly skilled ophthalmologists has helped the company build strong brand equity over the years. Combined with a comprehensive range of services and adoption of advanced technologies such as FEMTO Cataract and SMILE for refractive procedures, these factors have helped DAHCL maintain its leadership position with an estimated 25% market share of the organised eye care segment. Going forward, ICRA expects DAHCL to continue to benefit as consumer preferences shift from unorganised to organised chains for eye care treatment.

Strong financial profile – DAHCL's financial profile is characterised by a strong capital structure, healthy profitability and coverage metrics. Following the IPO in February 2025, the company reduced external borrowings significantly to Rs. 246.9 crore from Rs. 387.8 crore in FY2024, even as total debt including lease liabilities remained stable at Rs. 960.9 crore as on March 31, 2025. Backed by the growth in the number of centres, as on September 30, 2025, the total lease liabilities increased

to Rs. 802.9 crore while the external debt decreased to Rs. 179.8 crore from Rs. 246.9 crore as on March 31, 2025. Improved operating performance and enhanced liquidity position following the IPO has also supported deleveraging, with total debt (including lease liabilities)/OPBDITA improving to 1.9x as on September 30, 2025, from 2.1x as on March 31, 2025, and net debt/OPBDITA remaining stable at 1.3x as compared to 1.2x over the same period. Interest coverage also strengthened to 5.6x in H1 FY2026 over 4.1x in FY2025 on account of higher operating profits. While lease liabilities are expected to rise with the addition of new centres, DAHCL's ability to maintain healthy operating profitability and coverage ratios provides comfort.

Healthy long-term demand outlook for the healthcare industry – The Indian eye care industry, in line with the broader healthcare industry is expected to benefit from strong demand, driven by rising awareness, increasing screen time, early onset of cataract and growing adoption of premium procedures. DAHCL, with its extensive network of 253 domestic centres and 19 international facilities as on December 31, 2025, is well positioned to capitalise on these growth drivers.

Credit challenges

Sizeable capex plans towards addition of new facilities; pace of ramp up remains critical going forward – DAHCL has an aggressive expansion strategy, targeting 55+ new centres annually and plans of reconstructing its flagship Chennai COE. This entails a capex outlay of Rs. 380–400 crore in FY2026. While the capex is expected to be funded through internal accruals and existing liquidity, timely execution and healthy ramp-up of operations at the new centres will be critical to maintaining the company's profitability levels.

Stiff competition in the healthcare industry – The company faces stiff competition from other organised eye care chains, unorganised clinics and multi-specialty hospitals. This competitive landscape exerts pricing pressure on procedures such as cataract surgeries and exposes DAHCL to talent acquisition challenges. DAHCL's ability to retain skilled doctors and sustain favourable case mix along with patient footfalls will remain a key monitorable.

Exposed to regulatory risks inherent in the sector - Regulatory risks pertaining to restrictive pricing regulations levied by the Central and state government organisations could constrain the company's profit margins.

Environmental and social risks

Environmental risks: Although exposure to environmental risks remains low for entities in the healthcare industry, DAHCL is exposed to the risk of environmental impact arising from the discharge of biomedical, pollutant and hazardous waste.

Social risks: Exposure to social risks is moderate for the healthcare sector. Social risks for industry players include litigation exposure and high compliance standard requirements given the importance of the service being provided. Further, the regulatory nature such as price-control measures, could impact the earnings of industry players. Additionally, hiring and retaining quality human capital, who could drive patient footfalls, are key to earnings of industry players.

Liquidity position: Strong

DAHCL's liquidity profile is strong, supported by total cash and cash equivalents of Rs. 396.7 crore as on September 30, 2025 (including IPO proceeds of Rs. 43 crore) and its unutilised working capital (overdraft) limits of Rs. 9 crore as on September 30, 2025. Further, the company is expected to generate healthy cash flows, which, coupled with its existing liquidity levels should meet the funding requirement of the planned greenfield capex of around Rs. 380-400 crore in FY2026. The capex will be funded through a mix of internal accruals and existing cash balances. The company also has repayment obligations of Rs. 89.6 crore in FY2026 and Rs. 22.4 crore in FY2027. Further, funding mechanism for acquisitions (if any) will remain a key monitorable.

Rating sensitivities

Positive factors – The ratings could be upgraded if the company demonstrates a sustained improvement in its revenues and earnings supported by an improvement in the existing centres as well as healthy ramp up of greenfield centres being set up by the company/ acquisitions, while maintaining its comfortable credit metrics and liquidity position on a sustained basis.

Negative factors – Pressure could arise due to a sustained material deterioration in the margins or debt metrics. A specific trigger for a rating downgrade could be total debt (including lease liabilities)/OPBDITA of more than 3.0 times on a sustained basis.

Analytical approach

Analytical approach	Comments
Applicable rating methodologies	Corporate Credit Rating Methodology Hospitals
Parent/Group support	Not applicable
Consolidation/Standalone	For arriving at the ratings, ICRA has considered the consolidated financials of DAHCL. Refer to the Annexure II for the list of entities considered for consolidation.

About the company

Incorporated in 2010, Dr. Agarwals Health Care Limited (DAHCL) provides a comprehensive range of eye care services, including cataract, refractive and other surgeries, consultations, diagnosis and non-surgical treatments; and sells optical and eye care related pharmaceutical products. The group has a network of 272 facilities, as of December 31, 2025, of which 19 facilities are located outside India in Mauritius, Zambia, Tanzania, etc. The company operates in India, through a hub-and-spoke model wherein tertiary centres (hubs) and secondary centres are supported by primary facilities for diagnostics, consultations and selective procedures.

The group is led by the Chairman, Dr. Amar Agarwal, who has more than 35 years of clinical experience in the eye care services industry, and an experienced management team comprising of Dr. Adil Agarwal - Chief Executive Officer, Dr. Anosh Agarwal - Chief Operating Officer, Dr. Ashvin Agarwal – Chief Clinical Officer and Dr. Ashar Agarwal - Chief Business Officer.

DAHCL also has a listed Indian subsidiary, Dr. Agarwals Eye Hospital Limited (DAEHL). Incorporated in 1994, DAEHL is engaged in the business of providing eye care and related business, predominantly in Tamil Nadu. DAEHL is also a listed company. The company holds 72.67% shareholding in DAEHL as of December 31, 2025. In 2024, DAHCL acquired Dr. Thind Eye Care Private Limited (DTEPL) and currently holds around 51% shareholding in DTEPL as of March 2025.

Key financial indicators (audited)

DAHCL (Consolidated)	FY2024	FY2025	9M FY2026*
Operating income (OI)	1,332.2	1,711.0	1,516.0
PAT	95.1	110.3	118.2
OPBDIT/OI	27.6%	27.3%	26.9%
PAT/OI	7.1%	6.4%	7.8%
Total outside liabilities/Tangible net worth (times)	0.9	0.9	-
Total debt/OPBDIT (times)	2.6	2.1	-
Interest coverage (times)	3.7	4.1	-

Source: Company, ICRA Research; * Results; All ratios as per ICRA's calculations; Amount in Rs. crore; PAT: Profit after tax; OPBDIT: Operating profit before depreciation, interest, taxes and amortisation

Status of non-cooperation with previous CRA: Not applicable

Any other information: None

Rating history for past three years

Instrument	Type	Current rating (FY2026)				Chronology of rating history for the past 3 years					
		Amount rated (Rs crore)	FY2026			FY2025		FY2024		FY2023	
			Feb 23, 2026	Date	Rating	Date	Rating	Date	Rating	Date	Rating
Unallocated limits – Unallocated limits	Long term/ Short term	126.20	[ICRA]AA-(Stable)/ [ICRA]A1+	Oct 14, 2025	[ICRA]AA-(Stable)/ [ICRA]A1+	-	-	-	-	-	-
Fund-based – Term loan	Long term	73.80	[ICRA]AA-(Stable)	Oct 14, 2025	[ICRA]AA-(Stable)	-	-	-	-	-	-

Complexity level of the rated instruments

Instrument	Complexity indicator
Long term – Fund-based – Term loans	Simple
Long term/Short term – Unallocated	Not Applicable

The Complexity Indicator refers to the ease with which the returns associated with the rated instrument could be estimated. It does not indicate the risk related to the timely payments on the instrument, which is rather indicated by the instrument's credit rating. It also does not indicate the complexity associated with analysing an entity's financial, business, industry risks or complexity related to the structural, transactional or legal aspects. Details on the complexity levels of the instruments are available on ICRA's website: [Click here](#)

Annexure I: Instrument details

ISIN	Instrument name	Date of issuance	Coupon rate	Maturity	Amount rated (Rs. crore)	Current rating and outlook
NA	Term loan	FY2022-FY2023	8.5-8.9%	FY2029	73.80	[ICRA]AA- (Stable)
NA	Unallocated	NA	NA	NA	126.20	[ICRA]AA- (Stable)/ [ICRA]A1+

Source: Company

[Please click here to view details of lender-wise facilities rated by ICRA](#)

Annexure II: List of entities considered for consolidated analysis (as on December 31, 2025)

Company name	DAHCL ownership	Consolidation approach
Dr. Agarwal's Eye Hospital Limited (Subsidiary)	72.67%	Full Consolidation
Elisar Life Sciences Private Limited (Subsidiary)	93.18%	Full Consolidation
Dr. Thind Eye Care Private Limited (Subsidiary)	51.00%	Full Consolidation
Aditya Jyot Eye Hospital Private Limited (Subsidiary)	100%	Full Consolidation
Orbit Healthcare Services (Mauritius) Limited (Subsidiary)	100.00%	Full Consolidation
Orbit Healthcare Services (Ghana) Limited (Step-down subsidiary)	100.00%	Full Consolidation
Orbit Health Care Services (Kenya) Limited (Step-down subsidiary)	100.00%	Full Consolidation
Orbit Healthcare Services Mozambique Limitada (Step-down subsidiary)	97.00%	Full Consolidation
Orbit Health Care Services Limited, Rwanda (Step-down subsidiary)	100.00%	Full Consolidation
Orbit Healthcare Services Madagascar SARL (Step-down subsidiary)	80.00%	Full Consolidation
Orbit Healthcare Services (Tanzania) Limited (Step-down subsidiary)	100.00%	Full Consolidation
Orbit Health Care Services (Uganda) Limited (Step-down subsidiary)	100.00%	Full Consolidation
Orbit Health Care Services (Zambia) Limited (Step-down subsidiary)	100.00%	Full Consolidation

Source: Company

ANALYST CONTACTS

Jitin Makkar

+91 124 4545 300

jitinm@icraindia.com

Kinjal Shah

+91 22 6114 3400

kinjal.shah@icraindia.com

Mythri Macherla

+91 22 6114 3435

mythri.macherla@icraindia.com

Aman Mundhada

+91 22 6114 3471

aman.mundhada@icraindia.com

RELATIONSHIP CONTACT

L. Shivakumar

+91 22 6114 3406

shivakumar@icraindia.com

MEDIA AND PUBLIC RELATIONS CONTACT

Ms. Naznin Prodhani

Tel: +91 124 4545 860

communications@icraindia.com

HELPLINE FOR BUSINESS QUERIES

+91-9354738909 (open Monday to Friday, from 9:30 am to 6 pm)

info@icraindia.com

ABOUT ICRA LIMITED

ICRA Limited was set up in 1991 by leading financial/investment institutions, commercial banks and financial services companies as an independent and professional investment Information and Credit Rating Agency.

Today, ICRA and its subsidiaries together form the ICRA Group of Companies (Group ICRA). ICRA is a Public Limited Company, with its shares listed on the Bombay Stock Exchange and the National Stock Exchange. The international Credit Rating Agency Moody's Investors Service is ICRA's largest shareholder.

For more information, visit www.icra.in

ICRA Limited




Registered Office

B-710, Statesman House, 148 Barakhamba Road, New Delhi-110001

Tel: +91 11 23357940-45



Branches



© Copyright, 2026 ICRA Limited. All Rights Reserved.

Contents may be used freely with due acknowledgement to ICRA.

ICRA ratings should not be treated as recommendation to buy, sell or hold the rated debt instruments. ICRA ratings are subject to a process of surveillance, which may lead to revision in ratings. An ICRA rating is a symbolic indicator of ICRA's current opinion on the relative capability of the issuer concerned to timely service debts and obligations, with reference to the instrument rated. Please visit our website www.icra.in or contact any ICRA office for the latest information on ICRA ratings outstanding. All information contained herein has been obtained by ICRA from sources believed by it to be accurate and reliable, including the rated issuer. ICRA however has not conducted any audit of the rated issuer or of the information provided by it. While reasonable care has been taken to ensure that the information herein is true, such information is provided 'as is' without any warranty of any kind, and ICRA in particular, makes no representation or warranty, express or implied, as to the accuracy, timeliness or completeness of any such information. Also, ICRA or any of its group companies may have provided services other than rating to the issuer rated. All information contained herein must be construed solely as statements of opinion, and ICRA shall not be liable for any losses incurred by users from any use of this publication or its contents.